SYNC.L - Syncona Limited

LSE - LSE Delayed price. Currency in GBp
260.00
+2.00 (+0.78%)
At close: 4:35PM BST
Stock chart is not supported by your current browser
Previous close258.00
Open257.50
Bid235.00 x 0
Ask0.00 x 0
Day's range257.50 - 261.00
52-week range1.37 - 261.00
Volume296,196
Avg. volume6,178
Market cap1.716B
Beta-0.02
PE ratio (TTM)10.00
EPS (TTM)26.00
Earnings date4 Jul 2018 - 9 Jul 2018
Forward dividend & yield0.02 (0.83%)
Ex-dividend date2018-06-21
1y target est320.00
  • PR Newswire22 days ago

    Syncona Limited - Monthly Factsheet - May 2018

    Syncona Limited (a closed-ended investment company incorporated in Guernsey with registration number 55514) Monthly Fact Sheet May 2018   Attached is a link to the May 2018 Monthly Fact Sheet for Syncona ...

  • PR Newswire24 days ago

    Syncona Limited - Publication of 2018 Annual Report and Notice of AGM

    Syncona Limited (“Syncona”), a leading healthcare company focused on investing in and building global leaders in life science, today announces that it has published its Annual Report and Accounts for the year ended 31 March 2018 (“2018 Annual Report”). In addition, Syncona has published its Notice of Annual General Meeting 2018 and a circular relating to the 2018 Dividend.

  • PR Newswire29 days ago

    Syncona Limited - Autolus update on IPO

    Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, today notes that its portfolio company Autolus Therapeutics plc (“Autolus”) has today announced the pricing of its initial public offering (“IPO”) in the United States of 8,823,530 American Depositary Shares (“ADSs”), at an initial public offering price of $17.00 per ADS for total gross proceeds of approximately $150.0 million (£113.2 million1). All ADSs sold in the IPO were offered by Autolus.

  • PR Newswirelast month

    Syncona Limited - Syncona makes £85 million commitment to Freeline

    Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, today announces that it has committed £85m to Freeline in an £88.4 million Series B financing. Freeline is a leading, clinical stage AAV gene therapy company focused on liver expression for chronic systemic diseases.

  • PR Newswire3 months ago

    Syncona Limited - Blue Earth portfolio expansion, strong performance

    Syncona, a leading healthcare company focused on investing in and building global leaders in life science, is pleased to note that its portfolio company Blue Earth Diagnostics (Blue Earth) has signed a license for radiohybrid PSMA-targeted agent, rhPSMA-7, from Scintomics GmbH, Germany, a specialist in radiopharmaceuticals and radiopharmaceutical technologies. The move expands Blue Earth’s oncology portfolio, representing an opportunity to extend its leading position in prostate cancer imaging, including potential new areas of high unmet need, such as early stage primary prostate cancer patients.

  • PR Newswire4 months ago

    Syncona Limited - Monthly Factsheet - February 2018

    Syncona Limited (a closed-ended investment company incorporated in Guernsey with registration number 55514) Monthly Fact Sheet February 2018   Attached is a link to the February 2018 Monthly Fact Sheet ...

  • PR Newswire6 months ago

    Syncona Limited - Directors Dealings

    Syncona Limited LEI: 213800X8MBI5VQITLW60 Notification of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs") and Connected Persons 18 January 2018 1. Details of PDMR / ...

  • PR Newswire8 months ago

    Syncona Limited - Monthly Factsheet - October 2017

    Syncona Limited (a closed-ended investment company incorporated in Guernsey with registration number 55514) Monthly Fact Sheet October 2017 Attached is a link to the October 2017 Monthly Fact Sheet for ...

  • PR Newswire9 months ago

    Syncona Limited - Monthly Factsheet - September 2017

    Syncona Limited (a closed-ended investment company incorporated in Guernsey with registration number 55514) Monthly Fact Sheet September 2017 Attached is a link to the September  2017  Monthly Fact Sheet ...

  • PR Newswire10 months ago

    Syncona Limited - Nightstar announces closing of IPO

    Syncona Ltd (“Syncona”), a leading healthcare company focused on investing in and building global leaders in life science, today notes that its portfolio company Nightstar Therapeutics plc (“Nightstar”) has today announced the closing of its previously announced initial public offering in the United States of 6,164,000 American Depositary Shares (“ADSs”) representing 6,164,000 ordinary shares, at an initial public offering price of $14.00, which includes an additional 804,000 ADSs issued upon the exercise in full by the underwriters of their option to purchase additional ADSs. All of the ADSs were offered by Nightstar.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes